The Tampere-based company makes Glue4Life, a gel that gives cells a structure to grow and organize into tissue such as brain, liver, and nerve. Unlike the animal-derived gels common today, it is made from hyaluronic acid, has a precisely defined composition, and is easier to get approved for use in humans.

LifeGlue does not develop therapies itself. Instead, it supplies the material to companies and research groups that do. It began commercial operations in December 2024 and already has 15 paying customers in Europe, the US, and Australia.

“There are hundreds of companies and research groups in tissue engineering competing to be the first to get their graft to patients. We don’t have to guess the winner, because LifeGlue succeeds whenever any of them does,” says Janne Juhola, partner at Innovestor.

The funding will go toward production that meets Good Manufacturing Practice (GMP) standards, which customers need before taking tissues made with the material into clinical trials. The round includes angels from the Finnish, Estonian, and Lithuanian business angel networks, alongside Innovestor’s Angel Cofund.